Suzhou Ze Jing Biological Pharmaceutical

Suzhou, China Founded: 2009 • Age: 17 yrs
Company developing small molecules eukaryotic cell based recombinant protein drugs
Request Access

About Suzhou Ze Jing Biological Pharmaceutical

Suzhou Ze Jing Biological Pharmaceutical is a company based in Suzhou (China) founded in 2009.. Suzhou Ze Jing Biological Pharmaceutical has raised $61.92 million across 1 funding round from investors including Minsheng Life Insurance, Shenzhen Capital Group and Share Capital. Suzhou Ze Jing Biological Pharmaceutical operates in a competitive market with competitors including Merck, AbbVie, Lilly, Roche and Novo Nordisk, among others.

  • Headquarter Suzhou, China
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
Operational Areas
Healthcare → Healthcare Services & Infrastructure
Healthcare → Pharmaceuticals & Therapeutics
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $61.92 M (USD)

    in 1 rounds

  • Latest Funding Round
    $61.92 M (USD), Series B

    Jan 15, 2018

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Suzhou Ze Jing Biological Pharmaceutical

Suzhou Ze Jing Biological Pharmaceutical has successfully raised a total of $61.92M through 1 strategic funding round. The most recent funding activity was a Series B round of $61.92 million completed in January 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Series B — $61.9M
  • First Round

    (15 Jan 2018)

  • Investors Count 5
Date Amount Transaction Name Valuation Lead Investors Investors
Jan, 2018 Amount Series B - Suzhou Ze Jing Biological Pharmaceutical Valuation Minsheng Life Insurance , Shenzhen Capital Group
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Suzhou Ze Jing Biological Pharmaceutical

Suzhou Ze Jing Biological Pharmaceutical has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Minsheng Life Insurance, Shenzhen Capital Group and Share Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture capital, equity investment, and fund management services in China.
Founded Year Domain Location
A venture capital firm based in Shenzhen, China, is operated.
Founded Year Domain Location
Provider of early stage venture capital focused on technology companies
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Suzhou Ze Jing Biological Pharmaceutical

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Suzhou Ze Jing Biological Pharmaceutical

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Suzhou Ze Jing Biological Pharmaceutical Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Suzhou Ze Jing Biological Pharmaceutical

Suzhou Ze Jing Biological Pharmaceutical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, AbbVie, Lilly, Roche and Novo Nordisk, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Pharmaceutical products are manufactured and marketed worldwide.
domain founded_year HQ Location
Biopharmaceutical research and drug development are conducted globally by AbbVie.
domain founded_year HQ Location
Traditional pharmaceutical medicines are developed for multiple health fields.
domain founded_year HQ Location
Pharmaceuticals and diagnostics kits are developed for various diseases.
domain founded_year HQ Location
Drugs for diabetes, obesity, hemophilia, and hormone therapy are manufactured.
domain founded_year HQ Location
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Suzhou Ze Jing Biological Pharmaceutical

Frequently Asked Questions about Suzhou Ze Jing Biological Pharmaceutical

When was Suzhou Ze Jing Biological Pharmaceutical founded?

Suzhou Ze Jing Biological Pharmaceutical was founded in 2009 and raised its 1st funding round 9 years after it was founded.

Where is Suzhou Ze Jing Biological Pharmaceutical located?

Suzhou Ze Jing Biological Pharmaceutical is headquartered in Suzhou, China. It is registered at Suzhou, Jiangsu, China.

Is Suzhou Ze Jing Biological Pharmaceutical a funded company?

Suzhou Ze Jing Biological Pharmaceutical is a funded company, having raised a total of $61.92M across 1 funding round to date. The company's 1st funding round was a Series B of $61.92M, raised on Jan 15, 2018.

What does Suzhou Ze Jing Biological Pharmaceutical do?

Founded in 2009 in Suzhou, China, the biopharmaceutical firm focuses on small-molecule and recombinant protein drug development. Operations are divided between subsidiaries in Shanghai for small molecules and Suzhou for protein-based therapies. Key assets include Donafenib in phase III trials for cancer, Jaktinib in phase I for autoimmune diseases and cancer, and rhThrombin in phase I for surgical bleeding, alongside other candidates like ZG0320 and ZG001.

Who are the top competitors of Suzhou Ze Jing Biological Pharmaceutical?

Suzhou Ze Jing Biological Pharmaceutical's top competitors include Merck, Roivant Sciences and Amgen.

Who are Suzhou Ze Jing Biological Pharmaceutical's investors?

Suzhou Ze Jing Biological Pharmaceutical has 5 investors. Key investors include Minsheng Life Insurance, Shenzhen Capital Group, Share Capital, Zhongqing Guorong, and NLVC.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available